Bull
$2.48
Scenario price
$4.200
-0.254 (-6.04%)At close
Atomera Incorporated is engaged in the business of developing, commercializing and licensing processes and technologies for the semiconductor industry. The Company’s lead technology, named Mears Silicon Technology (MST) is a thin film of reengineered silicon, typically 100 to 300 angstroms (approximately 20 to 60 silicon atomic unit cells) thick. MST consists of layers of a non-semiconductor, such as oxygen, inserted into a semiconductor material, such as silicon, so that epitaxial growth is preserved. These layers can be used to modify or enhance the basic semiconductor properties and device attributes in a number of ways, including diffusion blocking, variability, mobility, gate leakage, and reliability, among others. MST can be used to create doping profiles. Its MSTcad is a Mathematical Model for the Synopsys Sentaurus Device Platform. MSTcad is available for Sentaurus Process and Device simulation packages, for physical and electrical characterization.
Atomera Inc is not a good buy right now. The current price is $4.20, and the RSI is at a very low 16.59, indicating oversold conditions. However, the company has faced significant revenue drops, with Q1 revenue plummeting to $11,000 from $50,000 last year, and incurred a net loss of $6.3 million in Q2 2026. The forward P/E ratio is 0, indicating no expected earnings growth, and the stock has seen a 12.13% decline over the last 5 days. The main risk is the ongoing commercialization challenges that have led to a disconnect between the business model and market demand, which could hinder future performance.
Craig-Hallum
$7
2024-07-31
Craig-Hallum
2024-07-31
Price Target
$7
Craig-Hallum
$17
2023-04-27
Craig-Hallum
2023-04-27
Price Target
$17
Craig-Hallum
—
2021-06-09
Craig-Hallum
2021-06-09
Price Target
—
Roth Capital
—
2018-10-18
Roth Capital
2018-10-18
Price Target
—
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

Atomera (ATOM) Q2 2026 Earnings Call Transcript

Atomera Q2 2026 Earnings Call Highlights

Investigation into Atomera Investor Losses

Atomera's Q1 Revenue Plummets Amid Commercialization Challenges

Atomera Q1 2026 Earnings Call Insights
Atomera Incorporated is engaged in the business of developing, commercializing and licensing processes and technologies for the semiconductor industry. The Company’s lead technology, named Mears Silicon Technology (MST) is a thin film of reengineered silicon, typically 100 to 300 angstroms (approximately 20 to 60 silicon atomic unit cells) thick. MST consists of layers of a non-semiconductor, such as oxygen, inserted into a semiconductor material, such as silicon, so that epitaxial growth is preserved. These layers can be used to modify or enhance the basic semiconductor properties and device attributes in a number of ways, including diffusion blocking, variability, mobility, gate leakage, and reliability, among others. MST can be used to create doping profiles. Its MSTcad is a Mathematical Model for the Synopsys Sentaurus Device Platform. MSTcad is available for Sentaurus Process and Device simulation packages, for physical and electrical characterization. It operates in the Technology sector (SEMICONDUCTORS & RELATED DEVICES industry).
Atomera Inc is not a good buy right now. The current price is $4.20, and the RSI is at a very low 16.59, indicating oversold conditions. However, the company has faced significant revenue drops, with Q1 revenue plummeting to $11,000 from $50,000 last year, and incurred a net loss of $6.3 million in Q2 2026. The forward P/E ratio is 0, indicating no expected earnings growth, and the stock has seen a 12.13% decline over the last 5 days. The main risk is the ongoing commercialization challenges that have led to a disconnect between the business model and market demand, which could hinder future performance.
1 analysts cover ATOM: 1 rate it Buy, 0 Hold and 0 Sell. The average price target is 5.00.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.